Core Viewpoint - The company has raised its revenue forecast for 2025 by 5.0% to 12.6 billion yuan, and its net profit forecast for 2026 has been increased by 274% to 6.68 billion yuan due to collaboration with Takeda, with a new net profit forecast for 2027 set at 4.14 billion yuan [1] Group 1 - The company forecasts a product revenue of approximately 11.9 billion yuan for 2025, representing a year-on-year growth of about 45%, with Q4 product revenue expected to be around 3.3 billion yuan, showing over 60% growth [2] - The company's product revenue has surpassed 10 billion yuan for the first time, driven by innovative products, with the oncology product portfolio expanding to 13 products by 2025 [3] - The company has seven products entering the national medical insurance directory for 2025, which will be implemented in 2026, indicating strong commercial momentum [4] Group 2 - The company is focusing on the continuous realization of innovative molecules like IBI363 and its internationalization process, with significant collaboration with Takeda worth 10 billion USD announced in October 2025 [5] - The company expects substantial profit growth in 2026 due to the anticipated progress in global development of IBI363 and other clinical trials [5]
中金：维持信达生物(01801)跑赢行业评级 目标价118.3港元